Teprotumumab

Teprotumumab is a fully human antibody developed by Genmab under our collaboration with Roche. Teprotumumab targets the Insulin-like Growth Factor-1 Receptor (IGF-1R), which is a well validated target. Clinical development of teprotumumab in ophthamalic indications will be conducted by River Vision Development Corporation, which licensed teprotumumab from Roche. Teprotumumab has been granted Orphan Drug Designation by the US FDA.

Back to top

Graves' orbitopathy is an autoimmune condition that is most commonly associated with hyperthyroidism, a disorder of the thyroid gland. Symptoms of Graves' orbitopathy include dry, watery, red eyes, double vision and other vision problems. Teprotumumab is being investigated in a Phase II study to treat Graves' orbitopathy. For more information on these studies, visit clinicaltrials.gov.

Back to top

Diabetic macular edema is a serious complication associated with diabetic retinopathy, the most common diabetic eye disease.  In the advanced stages of diabetic retinopathy, some patients’ blood vessels may swell and leak fluid into the macula, the part of the eye responsible for central high-resolution vision.  This condition is called diabetic macular edema and is the most common cause of visual loss in diabetic retinopathy.  It may even cause blindness if left untreated.  Teprotumumab is being investigated in a Phase I study to treat diabetic macular edema. For more information on studies of teprotumumab, visit clinicaltrials.gov.

Back to top